Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0946 • ACR Convergence 2021
Distinct Lipidomic Signatures in Synovium and Synovial Fluid of Patients with Rheumatoid Arthritis versus Psoriatic Arthritis
Beatriz Rocha¹, Berta Cillero-Pastor², Anna Illiano³, Valentina Calamia¹, Gabriella Pinto⁴, Angela Amoresano⁴, Cristina Ruiz-Romero⁵, Juan D Cañete⁶, Ron MA Heeren² and Francisco Blanco-García⁷, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006 A Coruña, España., A Coruña, Spain, ²The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands., Maastricht, Netherlands, ³CEINGE - Advanced Biotecnology, 80145 Napoli, Italy. Instituto Nazionale Biostrutture e Biosistemi (INBB), Rome, Italy., Naples, Italy, ⁴Department of Chemical Sciences, University of Naples “Federico II”, Napoli, Italy. Instituto Nazionale Biostrutture e Biosistemi (INBB), Rome, Italy, ⁵Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, ⁶Rheumatology Department, Hospital Clinic, Barcelona, Spain, ⁷Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain
Background/Purpose: The differential diagnosis of Rheumatoid Arthritis (RA) and Psoriatic arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of…
Abstract Number: 1015 • ACR Convergence 2021
Preclinical Investigation of the First-in-Class SIK2/SIK3 Inhibitor GLPG3970 in Models of Arthritis
Catherine Jagerschmidt¹, Stephanie Lavazais¹, Maikel Colli², Michael Drennan², Erik Verschueren², David Amantini¹, Nicolas Desroy¹ and Steve De Vos², ¹Galapagos SASU, Romainville, France, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: Improved management of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) remains an unmet need. Salt-inducible kinases (SIKs) modulate immune cells by a dual mechanism…
Abstract Number: 1127 • ACR Convergence 2021
Synovial Fluid Cytokines, Chemokines, and MMPs in Osteoarthritis Patients with Knee Pain Compared to RA Patients and Normal Knees
Richard Meehan¹, Elizabeth Regan¹, Eric Hoffman¹, Molly Wolff¹, Mary Gill¹, James Crooks², Presant Parmar³, Richard Scheuring⁴, John Hill⁵, karin Pacheco⁶ and Vijaya Knight⁷, ¹National Jewish Health, Denver, CO, ²National Jewsih Health and Colorado School of Public Health, Denver, CO, ³St Joeseph hospital/NJH, Denver, CO, ⁴NASA/JSC, Houston, TX, ⁵University of Colorado Sports Medicine, Denver, CO, ⁶Nationals Jewish Health, Denver, CO, ⁷Children's Hospital Department of Immunology, Denver, CO
Background/Purpose: A major limitation of synovial fluid (SF) biomarker studies in osteoarthritis (OA) has been difficulty in obtaining SF (SF) in patients with small effusions.…
Abstract Number: 1207 • ACR Convergence 2021
A Systematic Review Looking at the Relationship Between Serum Calprotectin and Ultrasound Parameters in Rheumatoid Arthritis
Andrea Hui Ling Low¹, Fang Yi Lim² and Margaret Ma³, ¹National University of Singapore, Singapore, Singapore, ²National Univeristy of Singapore, Singapore, Singapore, ³National University Hospital, Singapore, Singapore
Background/Purpose: Serum Calprotectin level has been shown to correlate with disease activity, ultrasound (US) parameters, treatment response and clinical remission in rheumatoid arthritis (RA). The…
Abstract Number: 1223 • ACR Convergence 2021
A Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies: 6-Month Effectiveness and Patient Reported Outcome Data from the European Cohort
Gerd Burmester¹, Bruno Fautrel², Rieke Alten³, Marco Matucci-Cerinic⁴, Jean hugues Salmon⁵, Thorsten Holzkaemper⁶, Inmaculada de la Torre⁷, Pedro Lopez-Romero⁸, Walid Fakhouri⁸ and Anja Gentzel-Jorczyk⁸, ¹Charité University Medicine Berlin, Berlin, Germany, ²Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ³Schlosspark-Klinik University, Berlin, Germany, ⁴University of Florence, Florence, Italy, ⁵Rheumatology, CHU Maison blanche, Reims, Reims, France, ⁶Eli Lilly and Company, Bad Homburg, Germany, ⁷Eli Lilly and Company, Alcobendas, Spain, ⁸Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (BARI) is a JAK1/2 inhibitor approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) and the treatment of…
Abstract Number: 1239 • ACR Convergence 2021
Differences in Patient-Reported Outcomes Between Those Who Stay in Remission and Those Who Have Disease-Worsening Following Therapy Withdrawal in Patients with Rheumatoid Arthritis
Vivian Bykerk¹, Jeffrey Curtis², Paul Emery³, Boulos Haraoui⁴, Elaine Karis⁵, Greg Kricorian⁵, David Collier⁶, Priscilla Yen⁵ and Bradley Stolshek⁵, ¹Hospital for Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ⁴Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen Inc., Simi Valley, CA
Background/Purpose: Patients with RA in remission (REM) may experience disease-worsening (DW) following therapy change or withdrawal. The change in patient-reported outcomes (PROs) after therapy withdrawal…
Abstract Number: 1255 • ACR Convergence 2021
A Molecular Signature Response Classifier Predicts the Likelihood of Non-response to TNF Inhibitor Therapies in RA at 3 Months
Stanley Cohen¹, Theodore Mellors², Lixia Zhang³, Alex Jones³, Erin Connolly-Strong⁴, Dimitrios Pappas⁵, Joel Kremer⁶, Johanna Withers³ and Viatcheslav Akmae³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Scipher Medicine, Waltham, TX, ³Scipher Medicine, Waltham, MA, ⁴Scipher Medicine, Austin, TX, ⁵CorEvitas, LLC, Waltham, MA, ⁶Albany Medical College, Latham, NY
Background/Purpose: Most people with rheumatoid arthritis (RA) are prescribed a TNF inhibitor (TNFi) as their first targeted therapy. A blood-based molecular signature response classifier (MSRC)…
Abstract Number: 1515 • ACR Convergence 2021
Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T Cells Are Expanded in Early Rheumatoid Arthritis and Correlate with Response to Treatment
Katie Williams¹, Annabelle Small², Qingxuan Song³, Suzanne Cole⁴, Ling-yang hao⁵, William Murray-Brown⁶, Susanna Proudman⁷, Malcolm Smith⁸, Sunil Nagpal⁹ and Mihir Wechalekar¹⁰, ¹Flinders University, Adelaide, Australia, ²Flinders University, Bedford Park, Australia, ³Janssen Research & Development LLC, Spring House, PA, ⁴Janssen Research, Adelaide, Australia, ⁵Janssen Research, Philadelphia, PA, ⁶GlaxoSmithKline, Adelaide, Australia, ⁷University of Adelaide, Medindie, Australia, ⁸Flinders Medical Centre, Adelaide, Australia, ⁹Janssen Research, Collegeville, PA, ¹⁰Flinders Medical Centre, Bedford Park, Australia
Background/Purpose: Programmed death protein 1 (PD-1) expressing T cells, including T follicular and T peripheral helper cells, are expanded in the circulation of individuals with…
Abstract Number: 1654 • ACR Convergence 2021
Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia
Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
Abstract Number: 1670 • ACR Convergence 2021
Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam², Ben Ponvilawan³, Pitchaporn Yingchoncharoen³ and Jerapas Thongpiya⁴, ¹Cleveland Clinic, Cleveland Heights, OH, ²Mount Auburn Hospital, Boston, MA, ³Mahidol University, Bangkok, Thailand, ⁴Mahdiol University, Bangkok, Thailand
Background/Purpose: Recent experimental studies have suggested that systemic inflammatory response could lead to impairment of lower esophageal function, resulting in gastroesophageal reflux disease (GERD). Epidemiologic…
Abstract Number: 1686 • ACR Convergence 2021
Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy
Eugen Feist¹, Saeed Fatenejad², Sergey Grishin³, Elena Korneva³, Michael Luggen⁴, Evgeniy Nasonov⁵, Mikhail Samsonov⁶ and Roy Fleischmann⁷, ¹Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ²SFC Medica, LLC, Charlotte, NC, ³R-Pharm, Moscow, Russia, ⁴Cincinnati Rheumatic Disease Study Group, Inc., and University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, ⁵V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, ⁶RPharm, Moscow, Russia, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Olokizumab (OKZ), a humanized monoclonal antibody targeting IL-6, was studied in patients with active Rheumatoid Arthritis (RA) despite methotrexate (MTX) (NCT02760368, NCT02760407) [1]. Here…
Abstract Number: 1702 • ACR Convergence 2021
Efficacy and Safety of Baricitinib in B/tsDMARDs Naive and B/tsDMARDs-IR Patients with Rheumatoid Arthritis
MASAOMI YAMASAKI, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan
Background/Purpose: Baricitinib, an oral selective inhibitor of Janus kinase (JAK) 1 and 2, improved signs and symptoms of rheumatoid arthritis(RA).We analyze efficacy and safety of…
Abstract Number: 1912 • ACR Convergence 2021
Meteorological Variables Have Different Effect on Core Measures of Disease Activity in Patients with Rheumatoid Arthritis
Peter Mandl¹, Paul Studenic², Farideh Alasti¹, Rainer Kaltenberger³, Andreas Kerschbaumer¹, Thomas Krennert³, Josef Smolen¹ and Daniel Aletaha⁴, ¹Medical University of Vienna, Vienna, Austria, ²Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ³Central Institute for Meteorology and Geodynamics, Vienna, Austria, ⁴Medical University Vienna, Vienna, Austria
Background/Purpose: The notion that weather conditions may influence the symptoms and course of rheumatic and musculoskeletal diseases goes back to ancient times. We aimed to…
Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Trishtha Peters¹ and Natasha Trehan², ¹University of Ontario, Toronto, ON, Canada, ²University of Ottawa, Toronto, ON, Canada
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
Abstract Number: 0014 • ACR Convergence 2021
Low Baseline Expression of Pyruvate Kinase and Succinate Dehydrogenase Genes in the Peripheral Blood of Rheumatoid Arthritis Patients Treated with Tofacitinib Is Associated with Clinical Remission at the End of Follow-up
Elena Tchetina¹, Azamat Satybaldyev², Galina Markova¹ and Alexander Lila², ¹Nasonova Research Institute of Rheumatology, Moscow, Russia, ²V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, which is characterized by erosive arthritis and systemic inflammation. Tofacitinib (TFCN) is a Janus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].